Keros Therapeutics Inc
KROS
查看详细走势图
17.570USD
+0.330+1.91%
收盘 02/06, 16:00（美东）报价延迟15分钟
713.91M总市值
11.03市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.91%
5天
-1.90%
1月
-5.33%
6月
+31.51%
今年开始到现在
-13.70%
1年
+61.79%
查看详细走势图
TradingKey Keros Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Keros Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名28/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价23.50。中期看，股价处于平稳状态。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Keros Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Keros Therapeutics Inc亮点
亮点风险
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
业绩增长期
公司处于发展阶段，最新年度总收入3.55M美元
利润高增长
公司净利润处于行业前列，最新年度总收入3.55M美元
估值高估
公司最新PE估值11.03，处于3年历史高位
机构减仓
最新机构持股29.79M股，环比减少50.36%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值1.96K
分析师目标
根据
10
位分析师
买入
评级
23.500
目标均价
+30.19%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Keros Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Keros Therapeutics Inc简介
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
公司代码KROS
公司Keros Therapeutics Inc
CEOSeehra (Jasbir)
网址https://www.kerostx.com/
相关品种
